← All Edesa Biotech, INC filings

Edesa Biotech, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
EDSA
Edesa Biotech, INC
10-K: Edesa Biotech Reports Strong EB05 Phase 3 Results, Raises Capital
Edesa Biotech announced positive Phase 3 results for its ARDS drug candidate EB05 and secured significant equity financing, but faces ongoing losses and a going concern warning.
NASDAQ
EDSA
Edesa Biotech, INC
10-K/A: Edesa Biotech Amends Annual Report to Disclose Additional Major Shareholder
Edesa Biotech has filed an amendment to its annual report to include an additional shareholder owning more than 5% of the company's common shares.
NASDAQ
EDSA
Edesa Biotech, INC
10-K: Edesa Biotech Reports Fiscal Year 2024 Results, Shifts Focus to General ARDS
Edesa Biotech's annual report highlights a strategic shift towards general ARDS research and development, alongside ongoing efforts in dermatology and pulmonary fibrosis.